



GOVERNMENT OF INDIA
CENTRAL DRUGS STANDARD CONTROL
ORGANISATION (Headquarter)
(Directorate General of Health Services)
Ministry of Health & Family Welfare
FDA Bhavan
ITO, Kotla Road
New Delhi - 110002 (Delhi)
Phone No.: 91-11-23216367
Fax No.: 91-11-23236973
E-Mail : dci@nic.in

File No. CT/22/000127

To,

M/s. AstraZeneca Pharma India Limited,
Block N1, 12th Floor Manyata Embassy,
Business Park, Rachenahalli Outer Ring Road,
Bangalore, Karnataka (India) – 560045.

Sir,

With reference to your application No. GCT/CT04/FF/2022/34427 (GCT/127/22) dated 18-10-2022, please find enclosed herewith the permission in Form CT-06 for conduct of clinical trial titled, **“A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA)”** Protocol No: D9185C00001, Version 1.0, dated 15/Sep/2022 and CSP Addendum IND-1, Version 1.0, dated 14/Oct/2022 with a total of up-to 100 subjects from India under the provisions of New Drugs and Clinical Trial Rules, 2019

The permission granted by the Central Licensing Authority to conduct clinical trial shall be subject to following conditions, namely:-

- (i) **DSMB shall actively & frequently monitor each subject enrolled in the study for adverse events especially in non-viral groups;**
- (ii) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licensing Authority under rule 8;
- (iii) where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:
Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be;
Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;
- (iv) in case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;

- (v) the Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- (vi) clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
- (vii) clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;
- (viii) status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- (ix) six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority electronically in the SUGAM portal;
- (x) in case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;
- (xi) any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;
- (xii) in case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;
- (xiii) in case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;
- (xiv) the premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorised by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
- (xv) where the new drug or investigational new drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;
- (xvi) the laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;
- (xvii) the Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
- (xviii) the sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.

- (xix) Merely granting permission to conduct the clinical trial with the Investigational Drug Product does not convey or imply that, based on the clinical trial study data generated with the investigational drug, permission to market this drug in the country will automatically be granted to you;
- (xx) The permission to initiate clinical trial granted under rule 22 in form CT-06 or automatic approval under rule 23 in Form CT 4A shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Yours faithfully,

RAJEEV SINGH Dr. Rajeev Singh (Raghuvanshi)
RAGHUVANSI Logistics Controller General (India) &
Stamp

Digitally signed by RAJEEV SINGH
RAGHUVAHINI
DN: cn=IN, o=Central Institute of
CONTROL ORGANIZATION, ou=RAJEEV SINGH
RAGHUVAHINI
2.5.4.20=80c268625e4ef89a39774cd605
3276904101a00634ef675b165b1b1
postalCode=600034, st=TAMIL NADU,
serialNumber=65A752A17049085D8F03BDC9C
2DE1FE73CFA12A1A126E9A94FA570112A419
013, cn=RAJEEV SINGH RAGHUVAHINI
Date: 2023.08.29 13:54:36 +05'30'

FORM CT-06

(See rules 22,25,26,29 and 30)

PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR
INVESTIGATIONAL NEW DRUG

1. The Central Licensing Authority hereby permits **M/s. AstraZeneca Pharma India Limited, Block NO 1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore, Karnataka (India) - 560045** to conduct clinical trial of the new drug or investigational new drug as per **Protocol No: D9185C00001, Version 1.0, dated 15/Sep/2022 and CSP Addendum IND-1, Version 1.0, dated 14/Oct/2022** in the below mentioned clinical trial sites [As per Annexure].-

2. Details of new drug or investigational new drug and clinical trial site [As per Annexure].

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi

Date _____

RAJEEV SINGH
RAGHUVANSHI
HI

Dr. Rajeev Singh Raghuvanshi
Drugs Controller General (India) &
Central Licensing Authority
Stamp

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: c=IN, o=CENTRAL DRUGS STANDARD
CONTROL ORGANIZATION, ou=RAJEEV SINGH
RAGHUVANSHI
2.5.4.20=80c62f6a23e4eafbe8a239774cdeb03c27
4b1015a0c65600000000000000000000
postalCode=600034, st=TAMIL NADU,
serialNumber=6375FA7004008508D24D5905
D0E1FE73CFA12A1255A69D15704124A59815,
cn=RAJEEV SINGH RAGHUVANSHI
Date: 2023.08.29 13:54:47 +05'30'

Note: The permission to initiate clinical trial granted under rule 22 in form CT-06 shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Annexure:

Details of new drug or investigational new drug:

Names of the new drug or investigational new drug	Tozorakimab (MEDI3506) or Placebo 150mg/mL (2mL/vial)
Therapeutic class:	Human IgG1 monoclonal antibody
Dosage form:	Solution for injection
Composition:	Tozorakimab (MEDI3506) = 150.0000 milligram (mg) In House Specification Active Water for injection = 53.5000 M U.S.P., Ph. Eur Inactive Polysorbate 80 = 0.0300 % w/v J.P., Ph. Eur Inactive L-Arginine hydrochloride = 220.0000 mM U.S.P., J.P., Ph. Eur Inactive L-Histidine hydrochloride monohydrate =16.8000 mM J.P., Ph. Eur Inactive L-Histidine = 3.2000 mM U.S.P., J.P., Ph. Eur Inactive

Indications:	Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
---------------------	--

Annexure:

Details of clinical trial site:

Sr. No.	Names and address of clinical trial site	Ethics committee details	Name of investigator
1.	Max Smart Super Speciality Hospital (A Unit of Gujarmal Modi Hospital and Research Centre), 1-2 Press Enclave Marg, Saket Institutional Area, Saket, New Delhi-110017, Delhi, India	Max Healthcare Ethics Committee, Ground Floor, Office of Ethics Committee, Max Super Speciality Hospital, Saket ECR/118/Inst/DL/2013/RR-19	Dr. Ritesh Agarwal
2.	Room No. 662, Department of Pulmonary Critical Care & Sleep Medicine, VMMC & Safdarjung Hospital, New Delhi-110029	Institutional Ethics Committee, Room No. 505 & 506, Old OPD Building, VMMC & Safdarjung Hospital, New Delhi-110029 ECR/593/Inst/DL/2014/RR-20	Dr. Rohit Kumar
3.	Medanta-The Medicity, CH Baktawar Singh Rd, Medicity, Islampur Colony, Sector-38, Gurugram, Haryana-122001	Medanta Institutional Ethics Committee (MIEC), 10 th Floor, A-wing (POCU), Medanta-The Medicity, Sector-38, Gurgaon, Haryana-122001 ECR/282/Inst/HR/2013/RR-20	Dr. Anand Jaiswal
4.	Grant Government Medical College & Sir JJ Group of Hospitals. JJ Marg, Byculla, Mumbai-400008, Maharashtra, India	Institutional Ethics Committee. Address:, GGMC, Mumbai Department of Pharmacology. Grant Government Medical College & Sir J.J group of Hospitals Byculla, Mumbai 400008, Maharashtra ECR/382/Inst/MH/2013/RR-19	Dr. Priti L. Meshram
5.	VHS Infectious Diseases Medical Centre, CART Clinical Research Site, Voluntary Health Services, Rajiv Gandhi Salai, Taramani, Chennai-600113	Institutional Ethics Committee The Voluntary Health Services, Multi-Speciality Hospital & Research Centre, Rajiv Gandhi Salai, Adyar, Chennai, Tamil Nadu-600113, India ECR/752/Inst/TN/2015/RR-22	Dr. Nagalingeswaran Kumarasamy

6.	Central United Hospital, Opposite odhav lake brts, Odhav, Ahmedabad- 382415	IEC GCS Medical College Hospital and Research Centre, GCS Medical College Hospital and Research Centre, Opp DRM Office Naroda Road Ahmedabad, Gujarat - 380025 India ECR/339/Inst/GJ/2013/RR-19	Dr. Parthiv Mehta
7.	Artemis Hospitals, Sector-51, Gurugram- 122001, Haryana, India	Artemis Health Sciences Institutional Ethics Committee, Artemis Hospitals, Sector-51, Gurugram-122001, Haryana, India ECR/53/Inst/HR/2013/RR-19	Dr. Reshma Tewari
8.	KLES Dr Prabhakar Kore Hospital and Medical Research Centre, Nehrunagar, Belagavi- 590010, Karnataka, India	KLE University's KLE PK Hospital, Nehrunagar, Belagavi- 590010, Karnataka, India ECR/211/Inst/KA/2013/RR-19	Dr. Jayaprakash Appajigol
9.	CIMS Hospital Pvt. Ltd., Plot No. 67/1, Opp. Panchamrut Bunglows, Near Shukan mall, Off Science City Road, Sola, Ahmedabad-380060	Ethics Committee of CIMS, CIMS Hospital Pvt. Ltd., Plot No. 67/1, Opp. Panchamrut Bunglows, Near Shukan mall, Off Science City Road, Sola, Ahmedabad-380060 ECR/206/Inst/GJ/2013/RR-20	Dr. Nilesh Shah
10.	Aware Gleneagles Global Hospital, 08-16-01, Near Sagar X Roads, Saroornagar, LB Nagar, Hyderabad-500035, Telangana	Institutional Ethics Committee, Gleneagles Global Hospital, 6-1- 1070/ 1 to 4 Lakdi ka Pool, Hyderabad-500004, Telangana, India ECR/158/Inst/AP/2013/RR-19	Dr. Sudhir Prasad
11.	T.N.M.C & B.Y.L Nair Ch. Hospital, 1 st Floor, Room No. 104, Medicine department Dr. A.L. Nair Road, Mumbai Central, Mumbai-400008	Institutional Ethics Committee, Topiwala National Medical College and B.Y.L. Nair Charitable Hospital, G Building, Ground Floor, Dr. A.L. Nair Road, Mumbai Central, Mumbai- 400008 ECR/22/Inst/Maha/2013/RR-19	Dr. Girish Rajadhyaksha
12.	Bhaktivedanta Hospital and Research Institute, Srishti Complex, Bhaktivedanta Swami Marg, Mira Road (E), Thane-401107	Bhaktivedanta Hospital Ethics Committee, Bhaktivedanta Hospital and Research Institute, Srishti Complex, Bhaktivedanta Swami Marg, Mira Road (E), Thane-401107	Dr. Ajay Madhav Godse

File No. CT/127/22-DCG(I)

		ECR/396/Inst/MH/2013/RR-19	
13.	SDS TRC & Rajiv Gandhi Institute of Chest Disease, 1 st Main Road, Someshwara Nagara, Bangalore-560029, India	Ethics Committee of SDS TRC & RGICD, SDS TRC & Rajiv Gandhi Institute of Chest Disease, 1 st Main Road, Someshwara Nagara, Bangalore-560029, India ECR/1700/Inst/KA/2022	Dr. Nagaraja C
